Richard N. Kender - 04 Mar 2026 Form 4 Insider Report for Seres Therapeutics, Inc. (MCRB)

Role
Interim Chief Executive Officer, Director
Signature
/s/ Thomas J. DesRosier, Attorney-in-Fact for Richard N. Kender
Issuer symbol
MCRB
Transactions as of
04 Mar 2026
Net transactions value
$0
Form type
4
Filing time
06 Mar 2026, 16:36:52 UTC
Previous filing
17 Jul 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Kender Richard N Interim Chief Executive Officer, Director C/O SERES THERAPEUTICS, INC., 101 CAMBRIDGE PARK DRIVE, CAMBRIDGE /s/ Thomas J. DesRosier, Attorney-in-Fact for Richard N. Kender 06 Mar 2026 0001381205

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MCRB Stock Option (right to buy) Award +150,000 $0.000000* 150,000 04 Mar 2026 Common Stock 150,000 $9.13 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests and become exercisable in 36 equal monthly installments.

Remarks:

Interim Chief Executive Officer